Meeting News CoverageVideo

VIDEO: Addition of elotuzumab to lenalidomide, dexamethasone safe, effective for myeloma

ORLANDO, Fla. — Paul G. Richardson, MD, offers insights into results of a study presented at the ASH Annual Meeting and Exposition that showed the addition of elotuzumab to lenalidomide and dexamethasone conferred sustained PFS benefits for patients with multiple myeloma.

ORLANDO, Fla. — Paul G. Richardson, MD, offers insights into results of a study presented at the ASH Annual Meeting and Exposition that showed the addition of elotuzumab to lenalidomide and dexamethasone conferred sustained PFS benefits for patients with multiple myeloma.

    See more from ASH Annual Meeting and Exposition